Risk of venous thromboembolism during the use of oral estrogen-progestogen hormone therapies in light of most recent research findings

Małgorzata Bińkowska; Artur Jakimiuk; Tomasz Paszkowski; Leszek Pawelczyk; Violetta Skrzypulec-Plinta

doi:10.5114/pm.2022.119861

eISSN: 2299-0038
ISSN: 1643-8876

Menopause Review/Przegląd Menopauzalny

Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

3/2022
vol. 21

Send email

Copy url:

abstract:

Review paper

Risk of venous thromboembolism during the use of oral estrogen-progestogen hormone therapies in light of most recent research findings

Małgorzata Bińkowska

¹

,

Artur Jakimiuk

^{2, 3}

,

Tomasz Paszkowski

⁴

,

Leszek Pawelczyk

⁵

,

Violetta Skrzypulec-Plinta

⁶

I Department of Obstetrics and Gynecology, Centre of Postgraduate Medical Education in Warsaw, Poland
Department of Obstetrics, Women’s Diseases and Oncological Gynecology, Central Clinical Hospital of the Ministry of Interior and Administration, Warsaw, Poland
Institute of Mother and Child, Center for Reproductive Health, Warsaw, Poland
III Chair and Department of Gynecology, Medical University of Lublin, Poland
Department of Infertility and Reproductive Endocrinology, Gynecology and Obstetrics Clinical Hospital of the Medical University in Poznan, Poland
Chair of Women’s Health, Medical University of Silesia in Katowice, Poland

Menopause Rev 2022; 21(3): 197-199

DOI: https://doi.org/10.5114/pm.2022.119861

Online publish date: 2022/10/01

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Bińkowska M, Jakimiuk A, Paszkowski T, Pawelczyk L, Skrzypulec-Plinta V. Risk of venous thromboembolism during the use of oral estrogen-progestogen hormone therapies in light of most recent research findings. Menopause Review/Przegląd Menopauzalny. 2022;21(3):197-199. doi:10.5114/pm.2022.119861.

APA

Bińkowska, M., Jakimiuk, A., Paszkowski, T., Pawelczyk, L.,  & Skrzypulec-Plinta, V. (2022). Risk of venous thromboembolism during the use of oral estrogen-progestogen hormone therapies in light of most recent research findings. Menopause Review/Przegląd Menopauzalny, 21(3), 197-199. https://doi.org/10.5114/pm.2022.119861

Chicago

Bińkowska, Małgorzata, Artur Jakimiuk, Tomasz Paszkowski, Leszek Pawelczyk,  and Violetta Skrzypulec-Plinta. 2022. "Risk of venous thromboembolism during the use of oral estrogen-progestogen hormone therapies in light of most recent research findings". Menopause Review/Przegląd Menopauzalny 21 (3): 197-199. doi:10.5114/pm.2022.119861.

Harvard

Bińkowska, M., Jakimiuk, A., Paszkowski, T., Pawelczyk, L.,  and Skrzypulec-Plinta, V. (2022). Risk of venous thromboembolism during the use of oral estrogen-progestogen hormone therapies in light of most recent research findings. Menopause Review/Przegląd Menopauzalny, 21(3), pp.197-199. https://doi.org/10.5114/pm.2022.119861

MLA

Bińkowska, Małgorzata et al. "Risk of venous thromboembolism during the use of oral estrogen-progestogen hormone therapies in light of most recent research findings." Menopause Review/Przegląd Menopauzalny, vol. 21, no. 3, 2022, pp. 197-199. doi:10.5114/pm.2022.119861.

Vancouver

Bińkowska M, Jakimiuk A, Paszkowski T, Pawelczyk L, Skrzypulec-Plinta V. Risk of venous thromboembolism during the use of oral estrogen-progestogen hormone therapies in light of most recent research findings. Menopause Review/Przegląd Menopauzalny. 2022;21(3):197-199. doi:10.5114/pm.2022.119861.

PlumX metrics:

Two important studies evaluating the safety profile of oral estrogen-progestogen hormonal therapies conducted in standard clinical practice with respect to the venous system were recently published.

A large prospective controlled cohort study (PRO-E2) based on the non-inferiority design has shown that the relative risk of developing venous thrombosis (VTE) in women using combined oral hormonal contraceptives (COHC) containing 17-estradiol (1.5 mg) and nomegestrol acetate (2.5 mg) (E2/NOMAC) was not statistically different from that in users of COHC containing ethinylestradiol and levonorgestrel (EE/LNG).

The aim of the recently presented study was to compare the risk of VTE in patients treated with a product for oral continuous combined menopausal hormone therapy containing 1 mg of 17ß-estradiol and 100 mg of micronized progesterone (1 mgE2/100 mgP4) with patients taking conjugated equine estrogens and medroxyprogesterone acetate (CEE/MPA). The study was based on an analysis of records retrieved from a US health insurance database, and was therefore concerned the real-life clinical practice. The hazard ratio of VTE when comparing 1 mgE2/100 mgP4 with CEE/MPA was 0.70 (95% CI: 0.53–0.92). The difference was found to be statistically significant (p < 0.05).

The rewieved studies provide further evidence that the use of hormones bioidentical with endogenous steroids in oral contraception and menopausal hormone therapy creates an opportunity to combine high efficacy with a favorable safety profile.

keywords:

Risk of venous thromboembolism during the use of oral estrogen-progestogen hormone therapies in light of most recent research findings

Małgorzata Bińkowska 1 , Artur Jakimiuk 2, 3 , Tomasz Paszkowski 4 , Leszek Pawelczyk 5 , Violetta Skrzypulec-Plinta 6

venous thromboembolism, combined oral hormonal contraception, menopausal hormone therapy

Małgorzata Bińkowska

¹

,

Artur Jakimiuk

^{2, 3}

,

Tomasz Paszkowski

⁴

,

Leszek Pawelczyk

⁵

,

Violetta Skrzypulec-Plinta

⁶